Jazz Pharmaceuticals to Participate in Upcoming November Investor Conferences

DUBLIN, Nov. 1, 2023 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following upcoming investor conferences:

Jefferies London Healthcare Conference on Tuesday, November 14, 2023

• Fireside chat at 4:30 a.m. PT / 7:30 a.m. ET / 12:30 p.m. GMT

6^th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023

• Fireside chat at 7:25 a.m. PT / 10:25 a.m. ET / 3:25 p.m. GMT

2023 BofA Leveraged Finance Conference on Wednesday, November 29, 2023

• Fireside chat at 7:10 a.m. PT / 10:10 a.m. ET / 3:10 p.m. GMT

Audio webcasts of the presentations will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. A replay of the webcasts will be archived on the website for 30 days.

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases – often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. Please visit www.jazzpharmaceuticals.com for more information.

Contacts:

Investors:
Andrea N. Flynn, Ph.D.
Vice President, Head, Investor Relations
Jazz Pharmaceuticals plc
[email protected]
Ireland +353 1 634 3211
U.S. +1 650 496 2717

Media:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
[email protected]
Ireland +353 1 637 2141
U.S. +1 215 867 4948

SOURCE Jazz Pharmaceuticals plc